Loading Page..

Knowledge Content Library

413
HIV Cure Initiative: Cost-Benefit Analysis
Sandy Wrobel, 2018 SDP Webinar (Invited Talk)

393
Multi Criteria Decision Analysis (MCDA) in healthcare
Kevin Marsh, Evidera, 2017 SDP Webinar (Invited Talk)

360
Capacity Planning in the Biopharmaceutical Industry
Phil Beccue, White Deer Partners, 2017 SDP Webinar (Invited Talk)

316
Decision Quality for Medical Device Companies and Their Regulators
Adam Seiver, 2016 SDP Webinar (Invited Talk)

314
Improving decision quality one decision at a time
Karen Sepucha and Leigh Simmons, 2015 SDP Webinar (Invited Talk)

313
On improving decision quality in medical sciences
Eyas Raddad and Charles Benson, 2015 SDP Webinar (Invited Talk)

309
Portfolio & Decision Analysis and the Fight Against Antimicrobial Resistance
Jon Mauer, 2015 SDP Webinar (Invited Talk)

118
A DA on the Use of Anti-coagulants for Children with Traumatic Brain Injuries
Rob Kleinbaum and Ian Mutchnick, 2014 SDP Webinar (Invited Talk)

15
I Love DA. I just wish we didn’t have to deal with people.
Stuart Harris, 2012 SDP Webinar (Invited Talk)

20
Probability Elicitation and Calibration in a Research & Development Portfolio: A 13-Year Case Study
Jay Andersen, 2011 SDP Webinar (Invited Talk)

28
East Coast DA Meets West Coast DA in Pharma Portfolio Decision Analysis
Jack M. Kloeber Jr., Bill Klimack, C. and Kwon Kim, 2010 SDP Webinar (Invited Talk)

443
Case Study: Self-Serve, Multi-Use Decision Frameworks: A Case Study Exemplifying the Top 5 Techniques
Case Study by Tyler Ludlow, Decision Skills Institute at 2019 DAAG Conference in Denver. This presentation will demonstrate the top 5 techniques for developing self-serve, multi-use decision frameworks by presenting the case of a pharmaceutical company looking to improve their quality assessment process of third-party contractors.

452
Life Sciences Track: Data and Decision Making in Drug Development
Panel discussion with David Wolter, IQVIA; Kirk Solo, Lexidyne Consulting; Thomas Abbott, Real World Informatics; Ian Bonzani, IQVIA at 2019 DAAG Conference in Denver. In this Life Sciences Mini-Conference, this talk covers what data are companies using and what new insights do they find most valuable?

429
Life Sciences Track: Why Do We Need DA When We Have AI?
Panel discussion with Joanna Wolkowski, Pfizer; Julie Schiffman, Pfizer; Leslie Lippard, Genetech; Pratap Khedkar, ZS Associates at 2019 DAAG Conference in Denver. In this Life Sciences Mini-Conference, this talk covers how would DA be used in the future? Will AI eventually replace decision professionals and decision-makers?

430
Life Sciences Track: How Sure Are You?: Epistemology of Clinical Research and DA
Fireside Chat with Steven Goodman, Stanford at 2019 DAAG Conference in Denver. In this Life Sciences Mini-Conference, this talk covers the reliance on classical statistics without bayesian considerations in epistemology studies in medical research.

374
I learned about DA from That!
Presented by Rodger Thompson (Pfizer) at 2017 DAAG Conference in New Orleans. In this session on Coaching and Knowledge Transfer, this talk covers lessons learned from over 20 years of DA practice, including communicating to management.

373
A "Cap & Trade" Approach to Assessing Technical Success Probabilities in Pharma
Presented by Chris Dalton (Syncopation Software) at 2017 DAAG Conference in New Orleans. In this session on Learning and Organization, this talk discusses probability assessment in the context of pharma/biotech R&D portfolio management.

371
The Value and Danger of “Story” in Getting to Commitment to Action
Presented by Elayne Ko (Pfizer) and Charles Persinger (Eli Lilly) at 2017 DAAG Conference in New Orleans. In this session on Facilitation and Collaboration, this talk discusses both the value and danger of using stories to facilitate commitment to action.

355
Modeling Ordered Uncertainties
Presented by Jon Mauer (Pfizer) at 2016 DAAG Conference in Banff. In this session on The Cutting Edge of Decision Analysis, this short talk looks at complex correlated uncertainties in a pharma problem.

325
Improved Drug Treatment Decisions Through Consistent Benefit‐Risk Tradeoffs
Presented by Jack Kloeber (Kromite) at 2016 DAAG Conference in Banff. In this session on Medical Decision Making, this talk discusses the use of multi-objective decision analysis to aid physicians in finding effective ways to measure and communicate the differences in treatment benefits and risks.

Stay connected